Completed NA INTERVENTIONAL 1-arm NCT01024959

Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result (PCA3)

Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result

Sponsor: Gen-Probe, Incorporated

Interventions PCA3 Assay

Updated 5 times since 2017 Last updated: Nov 6, 2012 Started: Aug 31, 2009 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Prostatic Neoplasms and is currently completed. Gen-Probe, Incorporated leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gen-Probe, Incorporated

Data source: Gen-Probe, Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aventura, United States , Cincinnati, United States , Columbus, United States , Garden City, United States , Houston, United States , Jeffersonville, United States , Los Angeles, United States , Naples, United States , Richmond, United States , San Antonio, United States and 3 more locations